Previous 10 | Next 10 |
2024-04-19 10:00:25 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Short interest in S&P 500 health stocks rises, Moderna among m...
2024-04-01 10:25:24 ET Predictive Oncology Inc. (POAI) Q4 2023 Earnings Conference Call April 01, 2024 08:30 A.M. ET Company Participants Glenn Garmont - IR Raymond F. Vennare - CEO and Chairman Josh Blacher - Interim CFO Conference Call Participants ...
2024-03-29 01:12:42 ET More on Predictive Oncology Financial information for Predictive Oncology Read the full article on Seeking Alpha For further details see: Predictive Oncology GAAP EPS of -$3.48, revenue of $1.78M
PITTSBURGH, March 28, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) , a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility, to accelerate onc...
Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...
Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...
PITTSBURGH, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that Raymond F. Vennare, Chief Executive Officer, will participate in three upcoming investor conferences. Please see below for additiona...
2024-01-18 12:09:01 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Artificial intelligence and penny stocks don’t necessarily go together like peanut butter and jelly, but there is some allure to AI penny stocks for risk-tolerant investors. In 2...
PITTSBURGH, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that Raymond F. Vennare, Chief Executive Officer, will present at the upcoming Biotech Showcase, in San Francisco, CA, on January 9, 2024...
2023-11-14 13:27:15 ET Predictive Oncology Inc. (POAI) Q3 2023 Earnings Conference Call November 14, 2023, 08:30 AM ET Company Participants Glenn Garmont - IR Raymond Vennare - CEO and Chairman Josh Blacher - CFO Conference Call Participants Present...
News, Short Squeeze, Breakout and More Instantly...
Predictive Oncology Inc. Company Name:
POAI Stock Symbol:
NASDAQ Market:
Predictive Oncology (NASDAQ: POAI) , a leader in AI-driven drug discovery and biologics, today announced the introduction of a new technology designed to express functional and stable G-Protein Coupled Receptors (“GPCRs”). GPCRs are cell surface membrane receptors believed to play a...
Company files expansive intellectual property protection for “Membrane Protein Factory” to produce purified and biologically active membrane proteins for drug development External sources value annual US GPCR market at nearly $3.5 billion in 2022, growing more than 5% annu...
Predictive Oncology (NASDAQ: POAI) , a leader in AI-driven drug discovery and biologics, today announced the availability of its unique 3D cell culture model to advance cancer drug discovery and enable future drug development. More closely mimicking human tissue architecture than traditional 2D a...